- Home
- OPFI vs NMRA Comparison
OPFI vs NMRA Comparison
Compare OPFI & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- NMRA
- Stock Information
- Founded
- OPFI 2009
- NMRA 2019
- Country
- OPFI United States
- NMRA United States
- Employees
- OPFI N/A
- NMRA N/A
- Industry
- OPFI Finance: Consumer Services
- NMRA
- Sector
- OPFI Finance
- NMRA
- Exchange
- OPFI Nasdaq
- NMRA Nasdaq
- Market Cap
- OPFI 205.2M
- NMRA 287.6M
- IPO Year
- OPFI N/A
- NMRA 2023
- Fundamental
- Price
- OPFI $11.60
- NMRA $0.64
- Analyst Decision
- OPFI Buy
- NMRA Buy
- Analyst Count
- OPFI 2
- NMRA 8
- Target Price
- OPFI $11.75
- NMRA $9.29
- AVG Volume (30 Days)
- OPFI 800.9K
- NMRA 876.3K
- Earning Date
- OPFI 05-07-2025
- NMRA 05-12-2025
- Dividend Yield
- OPFI 2.15%
- NMRA N/A
- EPS Growth
- OPFI N/A
- NMRA N/A
- EPS
- OPFI 0.36
- NMRA N/A
- Revenue
- OPFI $276,770,000.00
- NMRA N/A
- Revenue This Year
- OPFI $112.50
- NMRA N/A
- Revenue Next Year
- OPFI $7.84
- NMRA N/A
- P/E Ratio
- OPFI $32.25
- NMRA N/A
- Revenue Growth
- OPFI 22.23
- NMRA N/A
- 52 Week Low
- OPFI $2.82
- NMRA $0.62
- 52 Week High
- OPFI $17.73
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- OPFI 71.65
- NMRA 27.87
- Support Level
- OPFI $9.43
- NMRA $0.73
- Resistance Level
- OPFI $10.07
- NMRA $0.72
- Average True Range (ATR)
- OPFI 0.50
- NMRA 0.06
- MACD
- OPFI 0.30
- NMRA 0.02
- Stochastic Oscillator
- OPFI 84.41
- NMRA 4.91
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.